Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2016
Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C
14 July 2016 - Two week treatment with Epclusa provides high cure rates for all six hepatitis C genotypes. ...
Posted by Michael Wonder on 09 Jul 2016
Why the WHO plans a fair pricing model for drugs
7 July 2016 - Over the next year, the World Health Organization wants to develop a fair pricing model for pharmaceuticals. ...
Posted by Michael Wonder on 08 Jul 2016
European Commission grants marketing authorization for Gilead’s Epclusa (sofosbuvir/velpatasvir) for the treatment of all genotypes of chronic hepatitis C
8 July 2016 - Epclusa is the first and only all-oral, single tablet regimen for all genotypes (1-6) of chronic hepatitis ...
Posted by Michael Wonder on 01 Jul 2016
Expansion of hepatitis C drug coverage in Massachusetts
30 June 2016 - Today, the Commonwealth of Massachusetts is taking steps that increase Medicaid patients’ access to Hepatitis C medications. ...
Posted by Michael Wonder on 30 Jun 2016
New Zealand Pharmaceutical Schedule - 1 July 2016 update
1 July 2016 - The beginning of a new financial year sees the listing of some new medicines. ...
Posted by Michael Wonder on 28 Jun 2016
FDA approves Epclusa for treatment of chronic Hepatitis C virus infection
28 June 2016 - The U.S. FDA approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with ...
Posted by Michael Wonder on 15 Jun 2016
Hepatitis C sufferers’ ire at activist-website ban
14 June 2016 - A website which raises awareness about a medical cure for hepatitis C could be hidden from Australians. ...
Posted by Michael Wonder on 09 Jun 2016
Government announces new drug funding, including for advanced melanoma
9 June 2016 - Medicine to treat six diseases, including for advanced melanoma, will be available to New Zealanders. ...
Posted by Michael Wonder on 09 Jun 2016
Health sector feedback helps make the most of Government funding boost
9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements ...
Posted by Michael Wonder on 27 May 2016
Highlights from the CHMP 23-26 May 2016 meeting
27 May 2016 - Six medicines, including two combination therapies for chronic hepatitis C, recommended for approval. ...
Posted by Michael Wonder on 27 May 2016
Two new combination therapies against chronic hepatitis C
27 May 2016 - Direct-acting antivirals Epclusa and Zepatier recommended for approval. ...
Posted by Michael Wonder on 25 May 2016
Health Canada approves Daklinza (daclatasvir dihydrochloride) for difficult-to-treat hepatitis C patient populations
24 May 2016 - Daklinza is approved in Canada in combination with other agents for the treatment of chronic hepatitis C ...
Posted by Michael Wonder on 23 May 2016
Agenda for the May 2016 CHMP meeting
23 May 2016 - The agenda for the 23-26 May 2016 CHMP meeting is now available. ...
Posted by Michael Wonder on 04 May 2016
Proposals to list hepatitis C treatments
4 May 2016 - PHARMAC is seeking feedback on two proposals to list two new treatments for hepatitis C. ...
Posted by Michael Wonder on 01 May 2016
Schedule of Pharmaceutical Benefits - 1 May 2016 update
1 May 2016 - The May 2016 issue of the Schedule sees a number of new and revised listings. ...